Review

Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer’s disease

Alexandre Vallée1,2, Yves Lecarpentier3, Rémy Guillemin4, and Jean-Noël Vallée2,5,*

1Experimental and Clinical Neurosciences Laboratory, INSERM U1084, University of Poitiers, Poitiers, France, 2Laboratoire de Mathématiques et Applications (LMA), UMR CNRS 7348, Université de Poitiers, Poitiers, France, 3Centre de Recherche Clinique, Hôpital de Meaux, Meaux, France, 4Université de Poitiers et CHU de Poitiers, DACTIM, Laboratoire de Mathématiques et Applications, UMR CNRS 7348, SP2MI, Futuroscope, France, and 5CHU Amiens Picardie, Université Picardie Jules Verne (UPJV), Amiens, France

*Corresponding address. Tel: +33-3-22088000; E-mail: valleejn@gmail.com

Received 14 February 2017; Editorial Decision 20 April 2017

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disease, in which the primary etiology remains unknown. AD presents amyloid beta (Aβ) protein aggregation and neurofibrillary plaque deposits. AD shows oxidative stress and chronic inflammation. In AD, canonical Wingless-Int (Wnt)/β-catenin pathway is downregulated, whereas peroxisome proliferator-activated receptor γ (PPARγ) is increased. Downregulation of Wnt/β-catenin, through activation of glycogen synthase kinase-3β (GSK-3β) by Aβ, and inactivation of phosphatidylinositol 3-kinase/Akt signaling involve oxidative stress in AD. Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid from Cannabis sativa plant. In PC12 cells, Aβ-induced tau protein hyperphosphorylation is inhibited by CBD. This inhibition is associated with a downregulation of p-GSK-3β, an inhibitor of Wnt pathway. CBD may also increase Wnt/β-catenin by stimulation of PPARγ, inhibition of Aβ and ubiquitination of amyloid precursor protein. CBD attenuates oxidative stress and diminishes mitochondrial dysfunction and reactive oxygen species generation. CBD suppresses, through activation of PPARγ, pro-inflammatory signaling and may be a potential new candidate for AD therapy.

Key words: cannabidiol, Wnt/β-catenin pathway, PPARγ, Alzheimer’s disease, PI3K/Akt pathway, oxidative stress, neuroinflammation, GSK-3β

Introduction

Alzheimer’s disease (AD) is a neurodegenerative disease (ND), in which the primary etiology remains unknown. AD is marked by two main postmortem pathological phenomenons: amyloid beta (Aβ) protein aggregation forming plaque deposits and tau protein hyperphosphorylation resulting in neurofibrillary tangles (NFTs). Diminution of cognitive function, diminution of memory, and other neurobehavioral manifestations are common symptoms in AD [1]. Other behavioral and cognitive symptoms include social withdrawal, poor facial recognition ability, increased motor agitation, and likelihood of wandering [2,3]. Oxidative stress and chronic inflammation are considered as likely underlying causes of AD [4,5]. Increased oxidative stress may be an early indication of AD risk [6,7].
In AD, canonical Wingless-Int (Wnt)/β-catenin is downregulated, whereas peroxisome proliferator-activated receptor γ (PPARγ) is increased [8]. Conversely, other NDs, like Amyotrophic lateral sclerosis, have canonical Wnt/β-catenin pathway upregulated, while PPARγ is decreased [9]. Subsequently, NDs have recently been classified into these two categories, per the regulation of Wnt/β-catenin and PPARγ [10].

In AD, Aβ protein accumulation decreases Wnt/β-catenin pathway [11]. Downregulation of β-catenin reduces the expression of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway [12,13]. Inactivation of Wnt/β-catenin/PI3K/Akt pathway involves oxidative stress in mitochondria [14]. Thus, stimulating Wnt/β-catenin signaling could represent an interesting therapeutic target for AD [15,16].

PPARγ is upregulated in AD due to the neuroinflammation [17]. PPARγ agonists are utilized in AD and show beneficial effects [18,19]. The anti-inflammatory effect induced by PPARγ agonists may explain their positive effect in AD.

Cannabinoids belong to a heterogeneous group of compounds: endogenous, synthetic and phytocannabinoids [20,21]. Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid from Cannabis sativa plant. CBD can attenuate brain damage associated with neurodegeneration [22].

CBD reduces activation of GSK3-β, an inhibitor of Wnt pathway [23]. In AD PC12 cells, Aβ-induced tau protein hyperphosphorylation is inhibited by CBD. This effect involves increasing Wnt/β-catenin pathway and results in attenuation of oxidative stress [24,25].

Activation of PPARγ induces anti-inflammatory effects in AD [26]. CBD increases neuronal survival by reducing apoptosis and decreasing amyloid precursor protein (APP) level through activation of PPARγ receptors [27]. CBD can suppress pro-inflammatory pathway and neuroinflammation [28,29].

In this review, the links between CBD and the interplay canonical Wnt/β-catenin-PPARγ in AD are discussed.

**AD: Oxidative Stress and Neuroinflammation**

The pathological events of AD include senile plaques, due to the extracellular accumulation of Aβ protein [30], and NFTs, caused by the aggregation of hyperphosphorylated tau [31].

Aβ is mediated by the sequential cleavage of the APP, mediated by the β-secretase (BACE-1) and γ-secretase complex [32]. NFTs are composed of the aggregated hyperphosphorylated microtubule-associated protein (MAP) tau. Tau is a microtubule-stabilizing protein. Tau preserves neuronal cell structure and axonal transport. In AD, tau is disproportionately phosphorylated by several kinases, such as the glycogen synthase kinase-3β (GSK-3β), cyclin-dependent protein kinase-5 (CDK5), calmodulin-dependent protein kinase II (CAMKII), dual specificity tyrosine-phosphorylation-regulated kinase 1A, and mitogen-activated protein kinase proteins (MAPKs) are the best known [32–35].

Several pathways such as genetic factors, chronic inflammation induced-cytokine release, oxidative stress, and neurotoxicity elements have been proposed as likely underlying causes [4,5]. Aβ and NFTs generate chronic inflammatory response and oxidative damage, which enhance the progressive neurodegeneration. Increased oxidative stress may be an early indication of AD risk [6,7]. No effective therapies can counteract Aβ or hyperphosphorylated-tau formation, thus new therapeutic drugs are needed.

Mitochondrial damage in AD leads to excessive produce of reactive oxygen species (ROS) and lowered ATP production [36,37]. Mitochondrial defects damage the cell by increasing production and releasing ROS which cause cell damage and death by ATP depletion through decreased oxidative phosphorylation [38]. Oxidative stress and mitochondrial dysfunction involve dementia with cell death [39–41].

Aβ-induced oxidative stress alters cellular signaling pathways [42]. Incubation of the Aβ peptide induces a neurotoxic effect characterized by oxidative stress, apoptosis and damage to membrane and cytosolic proteins, mitochondrial DNA, and lipids [43].

Cell damage and worsening of cell signaling with accumulation of ROS in the cell can induce oxidative stress [42]. ROS provide essential molecular services. Neutrophils generate superoxide via NADPH oxidase, a membrane-associated enzyme, to sequester or eliminate pathogens [44]. Superoxide forms from oxidative phosphorylation present mitochondrial respiratory chain, especially in the sites of NADH dehydrogenase (complex I) [45]. Aβ causes a deficiency of both complex I (NADH dehydrogenase) and complex IV (cytochrome c oxidase). Complex I is one of the major ROS generation sites in mitochondria under normal physiological conditions, and changes in complex I function could be responsible for an increase in ROS production [46]. Mitochondrial-derived ROS and Aβ toxicity are strongly inhibited in resistant cells relative to sensitive cells. Through the repression of mitochondrial respiration, Aβ-resistant cells produce less ROS and show higher resistance to mitochondrial depolarization [14].

Amyloid oligomers induce lipid peroxidation and oxidative damage in proteins and biomolecules [47]. Alterations in the membrane, by Aβ accumulation, induce a massive influx of Ca2+, which alters the homeostasis of Ca2+ causing mitochondrial dysfunction, synapse loss, and neuronal death. Low levels of glutathione (GSH), in response to increased Ca2+ release, result in ROS accumulation [48]. Brain’s detoxification of ROS needs GSH redox cycling [49]. ROS activity affects DNA transcription by leading to DNA and related protein oxidation [50,51].

Tau induces mitochondrial dysfunction, severe ATP dysfunction, ROS and nitrogen species generation [52], which could also disturb the integrity of biological membranes and induce synaptic failure [53].

Higher levels of ROS enhance pro-inflammatory-induced transcription of genes and release cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α), leading to the neuroinflammation process [41]. Aβ-related inflammatory component of the pathology is considered to be a major target to regulate AD [54,55]. Aβ accumulation involves a chronic inflammatory state, causing damage and neuronal death [54,56].

**Inactivation of Wnt/β-Catenin and Activation of PPARγ in AD**

**Canonical Wnt/β-catenin pathway**

The Wnt pathway activity is observed in neural development for embryogenesis and in the mediation of neuronal homeostasis in adulthood [57–59]. The Wnt pathway is composed by a family of secreted lipid-modified glycoproteins, being strongly conserved across different species [60]. The canonical Wnt/β-catenin pathway plays a major role in metabolism, embryonic development, cell fate, and epithelial-mesenchymal transition. The canonical Wnt activity shows high level of β-catenin in the nucleus and/or cytosol, which can be observed by immunohistochemically staining and western blot analysis. Its dysregulation is implicated in several diseases, particularly in NDs [10]. Wnt family genes comprises 19 ligands which are departed in canonical Wnts and non-canonical Wnts. Canonical...
Wnt ligands (Wnt1, Wnt2, Wnt3, Wnt5a, Wnt8b, Wnt10a, and Wnt10b) are activators of the Wnt signaling. Wnt signaling activates the intracellular Wnt signaling (such as the β-catenin nuclear translocation), and secreted by neurons and immune cells in the central nervous system (CNS) [61]. Wnt ligands are composed by ~350–400 amino acids that contain an N-terminal signal peptide for secretion since they are lipid-modified secreted proteins [62].

β-Catenin/T-cell lymphoid enhancer (TCF/LEF) transcription is the main effector of the canonical Wnt pathway. The destruction complex is composed by Axin, tumor suppressor adenomatous polyposis coli (APC), and GSK-3β. It applies a strong control on the β-catenin pathway. In the absence of Wnt ligands (‘off state’), the destruction complex phosphorylates β-catenin for its degradation in the proteasome. In the presence of Wnt ligands (‘on state’), the Wnt receptor dimerizes with Frizzled (Fz) and LDL receptor-related protein 5/6 (LRP5/6). Wnt receptor is associated with Dishevelled (Dsh). This triggers the dysregulation of the destruction complex and hampers the degradation of β-catenin in the proteasome. Then, β-catenin translocates to the nucleus and dimerizes with TCF/LEF leading to the activation of β-catenin target genes such as PDK1, MCT-1, c-Myc, cyclin D1, Cox-2, and Axin2 [63–67].

Inflammation is a process age-related and associated with augmentation of GSK-3β activity and decreased Akt and Wnt/β-catenin pathways in the hippocampus of older rats [68]. GSK-3β and Dikkopf-1 (DKK1) are two inhibitors of the Wnt signaling [69–72]. DKK1 binds to LRP5/6 co-receptors for inhibition of Wnt signaling [73]. The β-catenin/TCF complex can regulate DKK1 transcription by a negative feedback loop [74]. GSK-3β is a neuron-specific intracellular serine-threonine kinase implicated in the control of many patho-physiological signalings (cell membrane signalling, neuronal polarity, and inflammation) [74–76]. GSK-3β inhibits β-catenin cytosolic stabilization and its translocation in the nucleus [77].

Inactivation of Wnt pathway in AD

Many studies show a downregulation of the Wnt/β-catenin signaling in the development of AD [8,67,77–80]. There is a decreased level of β-catenin and an increased activity of both GSK-3β and DKK1. Aβ induces dysfunction of Wnt pathway in AD [11,81,82]. Aβ favors DKK1, a secreted glycoprotein. In AD, DKK1 binds to LRP5/6, blocks the interaction of Wnt/Fzd and inhibits the interaction with Wnt ligands [83]. Increased DKK1 is observed in Alzheimer’s brain of humans and transgenic mice [8,24,84]. GSK-3β expression and activity are augmented in the hippocampus of AD patients [59,85]. In AD, GSK-3β phosphorylates MAP tau leading to NFTs [86–88]. In AD, increased GSK-3β decreases β-catenin level and increases tau phosphorylation and NFT formation [89]. Activation of GSK-3β favors the APP cleavage [90]. Cellular damages induced by Aβ are reversed by inhibition of GSK-3β [91]. GSK-3β has a critical role in AD, through the phosphorylation of tau and the promotion of Aβ production.

Inactivated Wnt/β-catenin pathway leads to oxidative stress in AD

Figure 1 summarizes the role of Wnt/β-catenin pathway in oxidative stress in AD. Oxidative damage and mitochondrial stress are important pathological events in the appearance of early AD [92]. In affected neurons, Aβ peptide accumulation promotes mitochondrial dysfunction, oxidative stress, and synaptic deteriorations [93]. Lowered ATP production by inactivation of Wnt pathway

Cerebral hypometabolism is correlated temporally with severity and has strong predictive interest for onset of dementia [94]. Decreases in transport of glucose and enzyme phosphorylation rate in AD brain could be due to a decreased ATP demand caused by synaptic dysfunction [14].

Glut-1 and Glut-3 play a major role in the insulin-sensitive homeostasis of glucose transport in the human brain [95]. Glut-3 is the main neuronal transporter of glucose [96]. Glut-1 and Glut-3 expressions are diminished in AD brain and are correlated with cerebral hypometabolism [97]. After entry into the cell, glucose is phosphorylated to glucose-6-phosphate by the enzyme hexokinase (HK). Amyloidogenic AD transgenic mouse models and postmortem human AD brain tissues show decreased levels of HK [98].

The final stage in glycolysis is the transformation of phosphoenolpyruvate (PEP) and ADP into pyruvate by the enzyme pyruvate kinase (PK). PK has four isoforms: PKM1, PKM2, PKL, and PKR. PKM2 shows low affinity with PEP [99]. Under high glucose concentration, PKM2 is acetylated, which diminishes its activity and targets it toward lysosome-dependent degradation [100]. Under high glucose concentration, peptide-aryl isomerase (Pin1) action stimulates PKM2 translocation to the nucleus [14]. Nuclear PKM2 binds β-catenin and then activates c-Myc-mediated expression of glycolytic enzymes such as Glut, lactate dehydrogenase A (LDH-A), pyruvate dehydrogenase kinase 1 (PDK1), and PKM2 [101]. PDK1 phosphorylates the pyruvate dehydrogenase complex (PDH), which is decreased and stops in the mitochondria the conversion of pyruvate into acetyl-CoA [102]. Activation of PI3K/Akt pathway is correlated with increased rate of glucose metabolism [103]. Activation of PI3K/Akt pathway stimulates hypoxia-inducible factor 1-alpha (HIF-1α) activity [104]. HIF-1α induction activates expression of Glut, LDH-A, PDK1, and PKM2 [103,105].

Accumulation of Aβ protein in the AD brain decreases levels of PI3K and Akt activity [106]. Aβ protein accumulation decreases Wnt and results in degradation of β-catenin [8,11]. Downregulation of β-catenin reduces the expression of PI3K/Akt signaling [12,13]. Aβ protein accumulation decreases the level of PI3K/Akt pathway signaling and results in inactivation of HIF-1α. Inactivation of HIF-1α involves PKM2 non-translocation to the nucleus. PKM2 inhibits PEP cascade and the formation of pyruvate. PKM2 does not bind with β-catenin and does not induce c-Myc-mediated expression of glycolytic enzymes (Glut, LDH-A, and PDK1). Hypometabolism of glucose and deficits in energy are observed in AD [107].

ROS accumulation and Wnt pathway

Pin1 dysregulation is observed in AD [108]. PKM2 is decreased by acute increases in intracellular concentrations of ROS by C358 oxidation, which enhances glucose flux and facilitates the production of the reducing molecule NADPH [103].

Upregulation of LDH-A leads to pyruvate being diverted towards the formation of lactate [109]. LDH-A activation produces NAD+ which sustains the NADH/NAD+ redox balance and allows continued glycolysis and biosynthetic reactions [110]. Production of ROS and oxidative stress resulting from apoptotic signaling is reduced by the transition from mitochondrial respiration to lactate production [111]. Recent studies have shown that nerve cells resistant to Aβ toxicity show a metabolic reprogramming and an activation of aerobic glycolysis through the stabilization of HIF-1α and upregulation of PDK1 and LDH-A [112,113]. Overexpression of PDK1 and LDH-A represses oxidative stress and confers resistance to Aβ toxicity [113,114].
Aβ toxicity, through inactivation of Wnt/β-catenin pathway, is associated with mitochondrial-derived ROS [14]. Forkhead class O (FoxO) transcription factors are major intracellular regulators of several metabolic pathways including production of glucose and the oxidative stress cellular response [115]. ROS inhibit Wnt/β-catenin pathway by hijacking β-catenin from TCF/LEF to FoxO [116]. This involves accumulation and binding of β-catenin to FoxO as a cofactor, and the activation of nuclear FoxO transcriptional activity [117,118]. FoxO activates the expression of apoptotic genes [119–121]. FoxO3a arrests cell cycle through the activation of the CDK inhibitor p27kip1 production and the repression of cyclin D1 expression [122,123]. FoxO activation results in induction of apoptosis [124]. Inhibition of FoxO protects against Aβ exposure [125].

Activation of the Wnt signaling can counter apoptosis through post-translational phosphorylation and sequestration of FoxO3a in the cytosol to inhibit the loss of mitochondrial membrane permeability, cytochrome c release, Bad phosphorylation, and activation of caspases [126].

Inactivated Wnt/β-catenin pathway leads to neuroinflammation in AD
Neuroinflammation is characterized by release of pro-inflammatory cytokines, blood-brain barrier breakdown and leukocyte infiltration in the brain [127]. Neuroinflammation contributes to neuronal degeneration [128]. Nuclear factor-kappa B (NF-κB) and pro-inflammatory
mediators including cytokines, and prostaglandins lead to chronic inflammation in the CNS [129–132]. In normal condition, Wnt pathway plays a role in inflammation-induced immune response [133]. A crosstalk exists between Wnt and NF-κB [134–139]. Wnt co-receptor LRPs contains an anti-inflammatory macrophage phenotype and can decrease monocyte differentiation into macrophage [140]. β-Catenin diminishes transcription of pro-inflammatory genes by inhibition of NF-κB. This action is regulated by GSK-3β. GSK-3β is a negative regulator of the β-catenin level and a positive regulator of the NF-κB signaling [141,142].

β-Catenin acts as a transcriptional activator by controlling the expression of anti-inflammatory genes. β-Catenin is considered as a target gene of PPARγ [135,143]. PPARγ agonists may exert an anti-inflammatory action by inhibiting the NF-κB-mediated transcription of downstream genes [144]. PPARγ stimulation decreases GSK-3β activity [145]. Many studies have suggested a crosstalk between PPARγ and GSK-3β [135,146–149]. In AD, diminution of β-catenin is correlated with the augmentation of NF-κB activity and neuroinflammation [150].

Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcriptional factor from the nuclear hormone receptor super family. PPARγ has been shown in several cell types, including adipose tissues, muscles, brain, and immune cells. A few endogenous ligands of PPARγ are identified, and these include fatty acids, phytanic acid, oxidized metabolites of linoleic acid, such as 9-hydroxy and 13-hydroxy octadecanoid acids (9-HODE and 13-HODE), polyunsaturated fatty acids (e.g. arachidonic acid), and eicosanoids [151–155]. Anandamide, an endogenous cannabinoid receptor ligand, interacts with PPARγ for differentiation of mouse 3T3-L1 fibroblasts into adipocytes [156]. The major endogenous ligand of PPARγ is 12-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) [151]. PPARγ ligands induce PPARγ heterodimer with retinoid X receptor (RXR), a nuclear receptor. The PPARγ–RXR complex changes PPARγ receptors, followed by its dissociation from corepressor molecules. The complex then binds with many coactivators or response elements, as PPAR response elements (PPREs). Therefore, PPARγ stimulates the expression of many genes and mediates glucose homoeostasis, insulin sensitivity, lipid metabolism, immune responses, cell fate, and inflammation [149,150]. PPARγ is strongly expressed in adipose tissue but scarcely expressed in heart, skeletal muscle, and liver [157–159]. PPARγ is lowly expressed in CNS and presents in many cell types such as neurons, astrocytes, oligodendrocytes, and microglia [160–162]. In neurons, PPARγ immunoreactivity appears mainly as a nuclear labeling although sometimes cytosolic staining is observed in some cortical neurons [163]. PPARγ agonist thiazolidinedione (TZD) ameliorates insulin sensitivity in peripheral tissues [164] and ameliorates glucose tolerance and insulin sensitivity in Type 2 diabetic patients [165]. TZDs interact with the promoters of glucose transporter (Glut2) and glucokinase (GK) in pancreatic β-cells and liver. Abnormalities of PPARγ have been shown in many pathological states like cancers, diabetes, obesity, and atherosclerosis. Some TZDs have served for Type 2 diabetes treatment. PPARγ also plays a major role in the regulation of cardiovascular rhythms through the control of blood pressure circadian variations and heart rate through Bmal1 [166,167].

PPARγ and neuroinflammation in AD
PPARγ levels are elevated in AD and play a role in the modulation of neuroinflammation [17]. PPARγ plays a role in regulating induced inflammatory responses, by inhibiting inflammatory cytokine production such as TNF, interleukin-1β (IL-1β), and IL-6, the production of nitric oxide and the expression of matrix metalloproteinase 9 and macrophage scavenger receptor 1 in many cell types, such as monocytes, macrophages, and epithelial cells [168,169].

Moreover, decreased level of Wnt signaling by GSK-3β activates NF-κB signaling and neuroinflammation [141,142]. Inhibition of Wnt/β-catenin pathway involves upregulation of PPARγ in many diseases such as AD or arrhythmogenic right ventricular cardiomyopathy (ARVC) [8,170,171]. γ-Catenin shares structural similarities with β-catenin [172], and it translocates to the nucleus, and competes with and inhibits β-catenin [173]. This phenomenon enhances adipogenesis and summarizes the phenotype of human ARVC [170,171].

PPARγ can induce anti-inflammatory effect and this leads to the hypothesis that PPARγ might be beneficial in CNS diseases presenting inflammatory processes, especially in AD [8]. Anti-inflammatory effects of PPARγ may be explained by the fact that PPARγ can inhibit several pathways by interacting directly with NF-κB, AP-1, STAT1, and NFAT [26,174]. PPARγ agonists diminish microglia Aβ activation and prevent hippocampal and cortical neurons from death [175–177]. PPARγ regulates inflammation of microglia due to Aβ [161]. High doses of PPARγ agonists diminish Aβ plaques [178]. Rosiglitazone, a PPARγ agonist, decreases Aβ-42 in ADs transgenic mice brain [19]. PPARγ activation increases APP ubiquitination and diminishes Aβ production [179]. Troglitazone, a PPARγ agonist, has an anti-inflammatory effect on neurons independently of its PPARγ activity [180].

Nonsteroidal anti-inflammatory drugs (NSAIDs) act directly on the generation of Aβ [181]. Ibuprofen inhibits GSK-3β, reverses the decrease in Wnt signaling due to Aβ and stabilizes β-catenin [182]. NSAIDs activate PPARγ and inhibit inflammatory processes in AD [183].

CBD and AD
Cannabidiol
Cannabinoids are a heterogeneous group of compounds classified into three main groups: endogenous, synthetic, and phytocannabinoids [20,21]. CBD is a non-psychotomimetic phytocannabinoid from Cannabis sativa plant. The Cannabis sativa plant produces more than 66 compounds, including especially delta9-tetrahydrocannabinol (THC), responsible for psychological effects, and CBD, the main non-psychotomimetic component in this plant [184]. CBD does not change blood pressure or temperature of body and does not induce psycho motor psychological function like THC [22]. CBD can attenuate brain damage associated with neurodegeneration. Animals and humans can tolerate high dose of CBD [22]. Moreover, CBD alters synaptic plasticity and stimulates neurogenesis. CBD effects are still not clear but seem involving several pharmacological targets. CBD shows a large spectrum of potential therapeutics properties such as anxiolytic, antidepressant, neuroprotective, anti-inflammatory, and immunomodulatory effects [185]. Cannabinoids may be considered as a new class of drugs because of their potential effects on neurodegenerative and neuropsychiatric disorders [20,186]. CBD has an interesting therapeutic action in neuropsychiatric disorders such as schizophrenia, epilepsy, addiction, and neonatal hypoxic-ischemic encephalopathy [187]. CBD can activate Wnt/β-catenin and PI3K/Akt pathways and produce therapeutic effects in schizophrenia [188–190].

CBD’s effects in AD models
CBD may be a potential promising candidate for AD therapy [191]. CBD promises potential for the multimodal treatment of AD.
through its neuroprotective, anti-inflammatory, and antioxidant properties [192–196]. CBD may counter many pathological AD symptoms. Indeed, many in vitro studies have shown that CBD treatment attenuates Aβ-induced neurotoxicity [24], tau protein-induced hyperphosphorylation [23], cell death and promotes hippocampal and adult neurogenesis [29,197]. CBD administration may reverse Aβ-induced memory impairments in rodents [198] and may reduce Aβ formation [27].

In neuroblastoma cells overexpressing APP (SHSY5YAPP+), CBD administration also reduces Aβ production by the promotion of its ubiquitination [27]. In vivo CBD treatment can reverse the cognitive deficits in a double transgenic AD mouse model (APP/PS1) [199]. CBD treatment during long-term can prevent the initiation of social recognition deficit in APP × PS1 mice [200]. CBD can be used as a long-term preventative AD treatment option and may be especially relevant for social withdrawal and facial recognition [200]. CBD reduces p38 MAPK phosphorylation and prevents nuclear NF-κB translocation and the transcription of pro-inflammatory genes [23].

Mesenchymal stem cells derived from gingival (GMSCs) have a high ability to differentiate into neural cells through their neural crest embryonic origin [201,202]. GMSCs are an attractive perspective for the treatment of AD [203]. CBD can generate the GMSC transcriptional profile of the genes correlated with AD. CBD treatment downregulates the expression of genes which encode kinases (GSK-3β, CMK, and MAPK) responsible for aberrant tau phosphorylation. CBD prevents tau hyperphosphorylation and subsequent NFT formation, by the reduction of the transcription level of these kinases. β-Secretase (BACE1) and γ-secretase, the genes coding for Aβ production, are also downregulated under CBD treatment [203]. Vanilloid receptor 1 (TRPV1) stimulation by CBD in GMSCs can activate PI3K/Akt signaling, which in turn inhibits GSK-3β by phosphorylating Ser9, thereby decreasing tau phosphorylation and Aβ production [203].

CBD: an anti-oxidative role via stimulation of Wnt pathway in AD

Aβ toxicity decreases PI3K/Akt pathway [14]. PI3K/Akt signaling is involved in GSK-3β activity regulation [204]. Cannabinoids can modulate the PI3K/Akt/GSK-3β axis [205,206]. Genes coding for the PI3K/Akt signaling are upregulated in GMSCs treated with CBD [203]. CBD inhibits the expression of GSK-3β by promoting PI3K/Akt signaling [203,207].

Cannabinoids exert anti-inflammatory function through endogenous receptors, such as cannabinoid receptor 1 (CB1) and CB2 [208]. Cannabinoids activate the PI3K/Akt pathway by binding with CB1 receptor on neurons and glial cells, and in a less manner with CB2 receptor in the body’s immune system [209,210]. THC is blocked by administration of rimonabant [211]. THC is a one-sided agonist of the CB1 receptor [212], while rimonabant is considered as an inverse agonist of CB1 receptor [213]. N-Oleoyl glycerol (OLGly), a lipamoenoic acid, increases adipoigenic genes such as PPARγ, and CB1 receptor mRNA expression. The decrease of CB1 receptor by SR141716 inhibits the actions of OLGly on PPARγ expression. OLGly increases Akt signaling pathway and decreases FoxO activity [214]. Nevertheless, several studies have demonstrated that CBD can prevent the negative actions of THC [215]. CBD also appears not to be rimonabant-like in its action [216]. The effects of CBD can be inverted by CB1 receptor inverse agonists and CBD may exert ‘indirect agonism’ at CB1 receptor [216]. However, several studies have demonstrated that CBD shows small binding affinity with the CB1 receptor [212,217]. CBD could not proceed by the CB1 receptor but possesses several other targets that can play a role in NDs or psychiatric disorders [218].

In AD, PI3K/Akt is downregulated via the inactivated Wnt/β-catenin pathway [106]. In PC12 cells, CBD induces neuroprotective effects on Aβ-induced toxicity [24]. CBD inhibits Aβ-induced tau protein hyperphosphorylation in PC12 cells. This action is correlated with the activity reduction of p-GSK-3β, the phosphorylated active form of GSK3-β, and results in increasing Wnt/β-catenin pathway [23]. Activation of this pathway can protect against Aβ neurotoxicity in AD [8,67,84,219–222].

CBD attenuates oxidative and nitrative stress, improves mitochondrial function and enhances mitochondrial biogenesis [223]. CBD attenuates oxidative stress through the attenuation of mitochondrial dysregulation and ROS generation or by the decrease of the expression of several ROS generating NADPH oxidase isoforms [225,224,225]. In a concentration-dependent manner, CBD stimulates cell survival, whereas diminishes ROS, nitrite production, lipid peroxidation, and inducible nitric oxide synthase (iNOS) protein expression [192].

However, inhibition of p-GSK-3β by CBD may be due to the antioxidant effects of CBD [24]. However, other antioxidants like vitamin C failed to relieve Wnt pathway in Aβ-stimulated PC12 cells [23,226]. Nevertheless, other antioxidants, which have a phenolic ring structure, such as vitamin E, can target the Wnt pathway [227]. It has been shown that CBD, which has a similar chemical structure as vitamin E, can decrease tau hyperphosphorylation not only with its antioxidant action but also through Wnt pathway increase [23]. However, DKK1 negatively modulates the canonical Wnt pathway. But, no data have been shown about the relationship between antioxidants and DKK1 [23].

CBD: an anti-inflammatory role via stimulation of PPARγ in AD

In vivo studies reported that CBD reduces Aβ-induced neuroinflammation in rats and mice [29,228]. Inflammation driven by the cytokines (TNF-α and IL-1β) is attenuated by CBD [198,228]. CBD modulates in vitro function of microglial cells and elicits beneficial effects in mice [229]. CBD can diminish lipopolysaccharide (LPS)-induced pro-inflammatory signaling in cultured microglial cells, such as NF-κB and STAT1 activation, while enhancing STAT3-related anti-inflammatory signaling [28]. Microglial cultures stimulated with the bacterial endotoxin LPS and treated with CBD show lower levels of cytokines like TNF-α, IL-1β, and IL-6 [28]. PPARγ modulates the expression of pro-inflammatory mediators such as NO, TNF-α, IL-1β, IL-6, iNOS, and COX-2 [230,231]. PPARγ activation represses NF-κB-mediated inflammatory signaling [232]. PPARγ is a molecular target for CBD and can be generated in mediating transcriptional effects in BV-2 microglial cells [233]. CBD also blocks reactive glosis by reducing glial stimulation and production of pro-inflammatory mediators [228]. This effect is linked to its possible action as a potent inhibitor of NF-κB stimulation induced by Aβ challenge [23].

CBD has antioxidant properties and neuroprotective effects by increasing cell viability and decreasing oxidative parameters. In PC12 cells stimulated by Aβ, pretreatment of CBD reduces ROS accumulation, lipid peroxidation, caspase-3 level, and DNA fragmentation [24].

CBD acts like a PPARγ agonist through receptor-dependent mechanisms [23,234,235]. PPARγ receptors are attractive drug
targets for inflammatory-associated neuropsychiatric disorders such as AD [235–237]. PPARγ receptors are involved in cellular proliferation, in apoptosis and in reduction of damage induced by ROS. Activation of PPARγ receptors inhibits transcription of pro-inflammatory genes and prevents the NF-κB pathway [235,236].

CBD prevents Aβ-induced neuronal death by reducing oxidative stress and ROS accumulation. PPARγ seems to induce the same effects as nuclear-erythroid-2-related factor 2 (Nrf-2) [187]. Nrf-2 and PPARγ regulate each other [186]. There are binding sites for Nrf-2 (antioxidant response elements) in the PPARγ promoter and PPREs in the Nrf-2 promoter [237]. Genes associated with oxidative stress are controlled by Nrf-2 [233]. CBD activates PPARγ and this effect is associated with impairment of the NF-κB pathway [238]. CBD also upregulates genes encoding negative regulators of NF-κB transcriptional activity through Nrf2 activation [233]. CBD, through activation of PPARγ, also decreases cell and neuronal death and promotes hippocampal neurogenesis in murine genetic model of AD [236]. Likewise, CBD increases neuronal survival by reducing apoptosis and decreasing APP level through activation of PPARγ receptors [27]. Traditional PPARγ agonists, such as TZD, diminish

![Diagram](https://example.com/diagram.png)

**Figure 2. Interactions between CBD and the interplay canonical Wnt/β-catenin and PPARγ in AD.** CBD inhibits Aβ, thus Aβ does not activate GSK-3β. CBD decreases GSK-3β activity, which leads to the increase of Wnt/β-catenin pathway and PI3K/Akt pathway and in diminution of oxidative stress in AD. CBD acts through PPAR gamma activation. CBD stimulates ubiquitination of APP and inhibition of Aβ. Inhibition of Aβ and GSK-3β inhibits tau protein and NFTs, which leads to the diminution of neuroinflammation in AD. AD, Alzheimer’s disease; APP, amyloid precursor protein; CBD, Cannabidiol; GSK-3β, glycogen synthase kinase-3β; PPARγ, peroxisome proliferator-activated receptor gamma; PI3K-Akt, phosphatidylinositol 3-kinase-protein kinase B; NFTs, neurofibrillary tangles.

<table>
<thead>
<tr>
<th>CBD effects in AD</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBD attenuates Aβ-induced neurotoxicity</td>
<td>[24,203]</td>
</tr>
<tr>
<td>CBD reduces Aβ formation and production</td>
<td>[27,198]</td>
</tr>
<tr>
<td>CBD attenuates tau protein-induced phosphorylation</td>
<td>[23,203]</td>
</tr>
<tr>
<td>CBD induces ubiquitination of APP protein</td>
<td>[27,201]</td>
</tr>
<tr>
<td>CBD attenuates neuroinflammation</td>
<td>[23,28,29,228,233–236,240]</td>
</tr>
<tr>
<td>CBD upregulates PPARγ activity</td>
<td>[23,29,228,234,244]</td>
</tr>
<tr>
<td>CBD increases survival and reduces apoptosis through PPARγ activation</td>
<td>[27]</td>
</tr>
<tr>
<td>Upregulation of PPARγ attenuates neuroinflammation</td>
<td>[8,26,161,174,180,183]</td>
</tr>
<tr>
<td>Upregulation of PPARγ decreases Aβ formation</td>
<td>[8,19,175–179]</td>
</tr>
<tr>
<td>CBD increases cell survival, decreases ROS, nitrite production, lipid peroxidation, and iNOS protein expression</td>
<td>[192]</td>
</tr>
<tr>
<td>CBD attenuates oxidative stress</td>
<td>[25,224,225,244]</td>
</tr>
<tr>
<td>CBD attenuates cytokines activity (TNFa, IL-1β)</td>
<td>[198,228,241–243]</td>
</tr>
<tr>
<td>CBD attenuates NF-κB transcriptional activity</td>
<td>[23,28,233,237]</td>
</tr>
<tr>
<td>CBD inhibits expression of GSK-3β by promoting PI3K/Akt signaling</td>
<td>[23,24,203–207]</td>
</tr>
<tr>
<td>CBD increases Wnt/β-catenin pathway</td>
<td>[23,24,227]</td>
</tr>
<tr>
<td>Activation of Wnt/β-catenin pathway protects against Aβ neurotoxicity and oxidative stress</td>
<td>[8,67,84,126,219–222]</td>
</tr>
</tbody>
</table>
the overproduction of NO, IL-6, and TNF-α as well as the augmented expression of the inducible enzymes iNOS and COX-2 induced in LPS-stimulated astrocytic and microglial cultures [238–240]. Through activation of PPARγ, CBD provokes a diminution of NO, TNF-α and IL-1β release with a diminution of glial fibrillary acidic protein, S100 calcium-binding protein B (S100B) and iNOS expression. The diminution of S100B induced by CBD and mediated by PPARγ is a major stage in the interruption of self-perpetuation of the reactive gliosis cycle in stopping self-perpetuation of the reactive gliosis cycle. The over-release of this astrogial-derived neurotrophin actively stimulates the pro-inflammatory cytokine loop generated by Aβ activation. This abundantly stimulates amyloidogenesis through the promotion of the cleavage of APP to Aβ, and generates tau hyperphosphorylation by dysregulation of the Wnt pathway [241–243]. PPARγ activation results in an inhibition of APP expression [173]. PPARγ upregulation promotes APP ubiquitination. CBD ubiquitination activity is controlled by PPARγ [27]. CBD induces the ubiquitination of APP protein, and this effect generates a diminution of APP full length protein level in SHSY5YAPP+ cells [27]. Figure 2 illustrates the anti-oxidative and anti-inflammatory roles of CBD in AD.

Conclusion and Perspectives

Table 1 summarizes the interactions of CBD with Wnt/β-catenin pathway and PPARγ in AD. The primary etiology of AD remains unknown; however, oxidative stress and chronic inflammation have been suggested as possible underlying causes of AD. AD is an ND in which canonical Wnt/β-catenin is downregulated while PPARγ is upregulated. Aβ protein accumulation decreases Wnt/β-catenin, while PPARγ is upregulated due to the neuroinflammation. Downregulation of Wnt/β-catenin pathway decreases PI3K/Akt pathway and glucose metabolism. This effect exacerbates oxidative stress in mitochondria and generates cell death. CBD inhibits GSK-3β and DKK1, two inhibitors of Wnt pathway. CBD administration increases Wnt/β-catenin pathway and diminishes oxidative stress in mitochondria. CBD induces the ubiquitination of APP protein through activation of PPARγ, decreases cell death and promotes hippocampal neurogenesis. PPARγ activation by CBD decreases neuroinflammation in AD. CBD may be a promising candidate for AD therapy by inhibiting oxidative stress and neuroinflammation through the interaction with Wnt/β-catenin and PPARγ.

References


114. Newington JT, Rappion T, Albers S, Wong DY, Rylett RJ, Cumming RC. Overexpression of pyruvate dehydrogenase kinase 1 and lactate...


162. Chiang MC, Chen CM, Lee MR. Modulation of energy de


176. Kim EJ, Kwon KJ, Park YJ, Lee SH, Moon CH, Baik EJ. Effects of peroxi-


baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. Cell Commun Signal 2010, 8: 12.


